Category: Pharmaceuticals
Great Lakes Pharmaceuticals Inc. plans to use the $3.1 million it raised in a Series B round to fund a pivotal clinical trial of its B-Lock anti-microbial catheter lock.
By Mary Vanac
Great Lakes Pharmaceuticals Inc. closed a $3.1 million Series B equity offering led by Charter Life Sciences, the Palo Alto, Calif.-based venture capital firm with an office in Cincinnati.
The company, formed by Case Western Reserve University, University Hospitals Case Medical Center and Ricerca Biosciences LLC in 2005, plans to use the investment to complete a pivotal clinical study of B-Lock, its anti-microbial catheter lock solution.
Thermo Fisher Scientific signs a five-year deal to provide pharma giant Eli Lilly with clinical trial supplies and services.
Thermo Fisher Scientific Inc. (NYSE:TMO) inked a five-year supply deal with Eli Lilly & Co. (NYSE:LLY) that will see it take over some of the pharma giant's clinical trial operations in Indianapolis.
Waltham, Mass.-based Thermo Fisher said its Fisher Clinical Services subsidiary will take over Lilly's in-house clinical trial materials manufacturing, packaging and labeling operations in the Circle City. That transition should be done some time this summer, and by the end of the year TMO will have taken over the clinical trial materials distribution throughout North America.
Unless you like opioid withdrawal; the world's smallest tweezers; the blind seeing the world using their tonuges; the world's smallest laser; and hands-free laparoscopic organ retraction.
Embeda is for chronic pain, not crushing and snorting: Newly approved Embeda (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules from King Pharmaceuticals Inc. ingeniously combines an opioid agonist (morphine) with an inner core of opioid antagonist (naltrexone). The naltrexone part of the capsule is sequestered, so it passes through the body with no intended clinical effect. But if any of you out there are thinking of crushing the capsule to enliven a slow night, please beware: The naltrexone will mix with morphine and give you an opioid withdrawal like you've never seen before.
Mansfield medical products giant rides generic painkiller sales to a strong second quarter, but predicts slow sales growth for the rest of the year.
It turns out that mother's little helper can give big companies a boost too. Or at least temporarily dull the pain of a deep recession.
Covidien Ltd. rode a rising tide of sales of oxycodone hydrochloride extended-release tablets — a generic Oxycontin equivalent — to a strong second quarter.
But the boost will be short-lived, thanks to a settlement the Mansfield-based medical products giant inked last year with Stamford, Conn.-based Perdue Pharma LP.